Breast cancer Cancer Breast
Conditions
Interventions
1. Group A: Arimidex (anastrozole) 1 mg plus tamoxifen placebo daily
2. Group B: Tamoxifen 20 mg plus Arimidex placebo daily
Sponsors
AstraZeneca Clinical Research Group (UK)
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Patients with locally advanced or metastatic breast cancer who are candidates to receive hormonal therapy as first line therapy for advanced disease (patients may have received adjuvant chemotherapy or hormonal therapy but patients who have received tamoxifen as adjuvant therapy must have an interval of at least 12 months since stopping tamoxifen and entry into this trial) 2. Post-menopausal defined as: 2.1 Aged >50 years or who have not menstruated during the preceding 12 months or who have follicle-stimulating hormone (FSH) levels within the post-menopausal range 2.2 Women aged 3 months 9. No treatment with a non-approved or experimental drug within the preceding 3 months before randomisation 10. No prior history of other malignancy other than breast cancer, except basal cell or squamous cell carcinoma of the skin or cancer of the cervix which has been satisfactorily controlled 11. No contraindications to protocol treatments
Exclusion criteria
Exclusion criteria: Not provided at time of registration
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Secondary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Countries
United Kingdom
Outcome results
None listed